227 related articles for article (PubMed ID: 22100312)
1. Indole RSK inhibitors. Part 1: discovery and initial SAR.
Boyer SJ; Burke J; Guo X; Kirrane TM; Snow RJ; Zhang Y; Sarko C; Soleymanzadeh L; Swinamer A; Westbrook J; Dicapua F; Padyana A; Cogan D; Gao A; Xiong Z; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):733-7. PubMed ID: 22100312
[TBL] [Abstract][Full Text] [Related]
2. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.
Kirrane TM; Boyer SJ; Burke J; Guo X; Snow RJ; Soleymanzadeh L; Swinamer A; Zhang Y; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):738-42. PubMed ID: 22056746
[TBL] [Abstract][Full Text] [Related]
3. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR studies of indole-based MK2 inhibitors.
Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300
[TBL] [Abstract][Full Text] [Related]
7. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
[TBL] [Abstract][Full Text] [Related]
8. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
[TBL] [Abstract][Full Text] [Related]
9. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
10. Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Liang GB; Qian X; Feng D; Biftu T; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 Apr; 17(7):1903-7. PubMed ID: 17291750
[TBL] [Abstract][Full Text] [Related]
11. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
12. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration.
Lu W; Liu X; Cao X; Xue M; Liu K; Zhao Z; Shen X; Jiang H; Xu Y; Huang J; Li H
J Med Chem; 2011 May; 54(10):3564-74. PubMed ID: 21488662
[TBL] [Abstract][Full Text] [Related]
13. Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors.
Fryer RM; Muthukumarana A; Chen RR; Smith JD; Mazurek SN; Harrington KE; Dinallo RM; Burke J; DiCapua FM; Guo X; Kirrane TM; Snow RJ; Zhang Y; Soleymanzadeh F; Madwed JB; Kashem MA; Kugler SZ; O'Neill MM; Harrison PC; Reinhart GA; Boyer SJ
J Pharmacol Exp Ther; 2012 Mar; 340(3):492-500. PubMed ID: 22128344
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.
Stachel SJ; Steele TG; Petrocchi A; Haugabook SJ; McGaughey G; Katharine Holloway M; Allison T; Munshi S; Zuck P; Colussi D; Tugasheva K; Wolfe A; Graham SL; Vacca JP
Bioorg Med Chem Lett; 2012 Jan; 22(1):240-4. PubMed ID: 22130130
[TBL] [Abstract][Full Text] [Related]
15. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
17. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
[TBL] [Abstract][Full Text] [Related]
19. Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
Zhong Y; Xue M; Zhao X; Yuan J; Liu X; Huang J; Zhao Z; Li H; Xu Y
Bioorg Med Chem; 2013 Apr; 21(7):1724-34. PubMed ID: 23434140
[TBL] [Abstract][Full Text] [Related]
20. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
